On October 26, 2020 Oasmia Pharmaceutical AB, an innovation-focused specialty pharmaceutical company, continues securing IP rights (Press release, Oasmia, OCT 26, 2020, View Source [SID1234568987]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
XMeNa patent approved in India and soon in Australia.
Registrations for Apealea approved in Switzerland, Israel, South Africa, Malaysia and Indonesia during 2020.
The XMeNa platform patent approved in further important markets
The XMeNa patent protects an improved method for producing Oasmia’s nanotechnology platform XR-17, which is a unique carrier system for anticancer drugs. The patent is crucial for Oasmia as it increases the exclusivity for the key technology XR‑17 and our lead product Apealea (paclitaxel micellar), which is being lauched in key markets globally.
The XMeNa patent is already approved in several major pharmaceutical markets, such as the US. Approval is furthermore pending in several other major markets around the world, such as Europe, Japan, China, Brasil and South Korea.
The patent was approved in India in September 2020 and the Australian patent office has issued a notice of acceptance, which means that a patent will be approved there soon.
The trademark portfolio for Apealea continues to grow – update on current registrations
Owning a distinguishable brand and trademark is an important part of establishing market and patient awareness at Oasmia. The Apealea trademark helps to build the long-term brand to enable increased sales and customer loyalty.
Apealea is a registered and protected trademark in the EU and the US. In 2020, additional registrations were approved for Apealea in Switzerland, Israel, South Africa, Malaysia and Indonesia.